Literature DB >> 2046821

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis.

P O Attman1, P Alaupovic.   

Abstract

To study the effect of renal function on the development of lipid and apolipoprotein abnormalities in human renal disease, we have investigated 75 patients at different stages of renal insufficiency. The patient population consisted of 19 patients with less advanced renal failure (CRF:1) characterized by a mean glomerular filtration rate (GFR) of 37.4 +/- 14 ml/min, 31 patients with advanced renal failure (CRF:2) having a mean GFR value of 7.9 +/- 7.3 ml/min and 25 patients on maintenance hemodialysis (CRF:HD). Patients in the CRF:1 group had normal plasma triglyceride (TG) and total cholesterol (TC) levels. In the CRF:2 and CRF:HD group, TG levels were increased two- to threefold, together with a moderate elevation of TC levels. All patient groups had elevated levels of VLDL cholesterol and slightly decreased levels of HDL cholesterol. The apolipoprotein profile of all patient groups was characterized by significantly reduced levels of apolipoprotein (Apo)A-I and ApoA-II and significantly increased levels of ApoC-III. CRF:2 and CRF:HD patients had also moderately elevated levels of ApoB, ApoC-I and ApoC-II. Levels of ApoE were only elevated in CRF:HD patients. All patients, regardless of TG levels, had significantly lower ApoA-I/ApoC-III ratios than controls. GFR was positively correlated with ApoA-I and inversely correlated with TC, TG and ApoC-III. CRF:HD patients had slightly higher ApoA-I and ApoA-II and lower ApoB levels compared to CRF:2 patients. Patients with vascular disease had higher TC, TG, ApoB, ApoC-II and ApoE than patients without vascular disease. These results demonstrate that the dyslipoproteinemia with CRF is already manifested at the early stages of disease through its abnormal apolipoprotein rather than lipid profile.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046821     DOI: 10.1159/000186303

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  31 in total

1.  Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.

Authors:  Nosratola D Vaziri; Kaveh Navab; Pavan Gollapudi; Hamid Moradi; Madeleine V Pahl; Cyril H Barton; Alan M Fogelman; Mohamad Navab
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

2.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 3.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

4.  Serum apolipoprotein B is inversely associated with eccentric left ventricular hypertrophy in peritoneal dialysis patients.

Authors:  Min Ye; Yanqiu Liu; Haoyu Wang; Na Tian; Wei Li; Wei He; Hong Lin; Rui Fan; Cuiling Li; Donghong Liu; Fengjuan Yao
Journal:  Int Urol Nephrol       Date:  2017-11-10       Impact factor: 2.370

Review 5.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

6.  Relationship between lipid profiles and kidney function in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; O Heikkilä; K Pettersson-Fernholm; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

7.  High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis.

Authors:  Jozélio Freire de Carvalho; Eloísa Bonfá; Mailze C Bezerra; Rosa Maria Rodrigues Pereira
Journal:  Clin Rheumatol       Date:  2009-03-13       Impact factor: 2.980

8.  Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.

Authors:  Hamid Moradi; Hamid M Said; Nosratola D Vaziri
Journal:  Transl Res       Date:  2012-12-03       Impact factor: 7.012

Review 9.  Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Authors:  Nosratola D Vaziri; Keith C Norris
Journal:  Blood Purif       Date:  2013-01-22       Impact factor: 2.614

10.  Lack of antilipoprotein lipase antibodies in Takayasu's arteritis.

Authors:  Jozélio Freire de Carvalho; Rosa Maria Rodrigues Pereira; Vilma Santos Trindade Viana; Eloísa Bonfá; Yehuda Shoenfeld
Journal:  Clin Dev Immunol       Date:  2009-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.